Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma
NCT00098332
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
INDUSTRY
Sponsor class
Conditions
Lymphoma
Interventions
DRUG:
forodesine hydrochloride
Sponsor
BioCryst Pharmaceuticals